CA2421321A1 - Peptides associes a la molecule hla-dr de cmh de classe ii et intervenant dans l'arthrite rhumatoide - Google Patents

Peptides associes a la molecule hla-dr de cmh de classe ii et intervenant dans l'arthrite rhumatoide Download PDF

Info

Publication number
CA2421321A1
CA2421321A1 CA002421321A CA2421321A CA2421321A1 CA 2421321 A1 CA2421321 A1 CA 2421321A1 CA 002421321 A CA002421321 A CA 002421321A CA 2421321 A CA2421321 A CA 2421321A CA 2421321 A1 CA2421321 A1 CA 2421321A1
Authority
CA
Canada
Prior art keywords
seq
peptide
citrullinated
mhc class
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002421321A
Other languages
English (en)
Inventor
Jonathan Hill
Ewa Cairns
David Bell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
London Health Sciences Centre Research Inc
Original Assignee
London Health Sciences Centre Research Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by London Health Sciences Centre Research Inc filed Critical London Health Sciences Centre Research Inc
Priority to CA002421321A priority Critical patent/CA2421321A1/fr
Publication of CA2421321A1 publication Critical patent/CA2421321A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/75—Fibrinogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rehabilitation Therapy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
CA002421321A 2003-03-07 2003-03-07 Peptides associes a la molecule hla-dr de cmh de classe ii et intervenant dans l'arthrite rhumatoide Abandoned CA2421321A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA002421321A CA2421321A1 (fr) 2003-03-07 2003-03-07 Peptides associes a la molecule hla-dr de cmh de classe ii et intervenant dans l'arthrite rhumatoide

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CA002421321A CA2421321A1 (fr) 2003-03-07 2003-03-07 Peptides associes a la molecule hla-dr de cmh de classe ii et intervenant dans l'arthrite rhumatoide

Publications (1)

Publication Number Publication Date
CA2421321A1 true CA2421321A1 (fr) 2004-09-07

Family

ID=32932232

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002421321A Abandoned CA2421321A1 (fr) 2003-03-07 2003-03-07 Peptides associes a la molecule hla-dr de cmh de classe ii et intervenant dans l'arthrite rhumatoide

Country Status (1)

Country Link
CA (1) CA2421321A1 (fr)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010005293A1 (fr) * 2008-06-16 2010-01-14 Chiralix B.V. Inhibiteurs de la peptidylarginine désiminase (pad)
WO2013138871A1 (fr) 2012-03-23 2013-09-26 The University Of Queensland Agent immunomodulateur et ses utilisations
WO2015181393A1 (fr) * 2014-05-30 2015-12-03 Per-Johan Jakobsson Nouveaux peptides à base de sfti et cyclotide
CN107490698A (zh) * 2017-09-15 2017-12-19 广州市雷德生物科技有限公司 一种检测试剂盒及其应用
CN111868073A (zh) * 2019-05-31 2020-10-30 广州市雷德生物科技有限公司 一种类风湿关节炎相关的特异性多肽及其应用
WO2022255929A1 (fr) * 2021-06-01 2022-12-08 Stiftelsen Vectis Nouveaux mimétiques peptidiques et leur utilisation

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010005293A1 (fr) * 2008-06-16 2010-01-14 Chiralix B.V. Inhibiteurs de la peptidylarginine désiminase (pad)
US8404647B2 (en) 2008-06-16 2013-03-26 Chiralix B.V. Peptidylarginine deiminase (PAD) inhibitors
WO2013138871A1 (fr) 2012-03-23 2013-09-26 The University Of Queensland Agent immunomodulateur et ses utilisations
EP2827890A4 (fr) * 2012-03-23 2015-11-25 Univ Queensland Agent immunomodulateur et ses utilisations
WO2015181393A1 (fr) * 2014-05-30 2015-12-03 Per-Johan Jakobsson Nouveaux peptides à base de sfti et cyclotide
CN107490698A (zh) * 2017-09-15 2017-12-19 广州市雷德生物科技有限公司 一种检测试剂盒及其应用
CN111868073A (zh) * 2019-05-31 2020-10-30 广州市雷德生物科技有限公司 一种类风湿关节炎相关的特异性多肽及其应用
CN111868073B (zh) * 2019-05-31 2021-04-30 广州市雷德生物科技有限公司 一种类风湿关节炎相关的特异性多肽及其应用
WO2022255929A1 (fr) * 2021-06-01 2022-12-08 Stiftelsen Vectis Nouveaux mimétiques peptidiques et leur utilisation

Similar Documents

Publication Publication Date Title
US20170267740A1 (en) Peptides associated with hla-dr mhc class ii molecule and involved in rheumatoid arthritis
US20200407424A1 (en) Novel complexes of types of mhc class ii that bind to collagen type ii peptides and their use on diagnosis and treatment
Fairchild et al. An autoantigenic T cell epitope forms unstable complexes with class II MHC: a novel route for escape from tolerance induction
US5888512A (en) Lymphocyte activity regulation by HLA peptides
US20030171280A1 (en) Compositions and methods for modulation of immune responses
Bach et al. High affinity presentation of an autoantigenic peptide in type I diabetes by an HLA class II protein encoded in a haplotype protecting from disease
JP2003517284A (ja) 免疫応答を変調する方法及び組成物
US20100203109A1 (en) Methods and Compositions for Treating Melanoma
EP0753005B1 (fr) Regulation de l'activite des lymphocytes t cytotoxiques par des peptides de cmh de classe i
KR100769338B1 (ko) 류마티스성 관절염（ｒａ） 항원성 펩타이드
CA2421321A1 (fr) Peptides associes a la molecule hla-dr de cmh de classe ii et intervenant dans l'arthrite rhumatoide
EP0832127B1 (fr) Peptides synthetiques et compositions pharmaceutiques contenant ces peptides
CA2477312C (fr) Utilisation de fgl2 soluble en tant qu'immunosuppresseur
US8658177B2 (en) Promiscuous HER-2/Neu CD4 T cell epitopes
US20220145281A1 (en) New vaccinal strategy to prevent or treat rhumatoid arthritis
US20050287631A1 (en) Compositions and methods related to a dimeric MHC class I and II-Like molecule (dsMHCI and dsMHCII)
WO1997004798A1 (fr) Epitopes derives de h-y et leur utilisation
Corrigall et al. BiP, a negative regulator involved in rheumatoid arthritis
Grueneberg The interaction of HLA-DM with conventional MHC class II molecules
AlTENSCHMIDTI et al. Antigen Processing/Presentation

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead

Effective date: 20190205